Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-UMIN000059341) titled 'A Prospective, Real-World Study Evaluating the Impact of RISankizumab on BurdEn of Disease in Ulcerative Colitis in JaPan (RISE UP)' on Oct. 8.
Study Type: Observational
Study Design:
Not selected Not selected
Primary Sponsor: AbbVie GK
Condition:
Ulcerative colitis
Recruitment Status: Recruiting
Phase: Not applicable
Date of First Enrollment: 2025/09/30
Target Sample Size: 200
Countries of Recruitment:
Japan
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067805
Published by HT Digital Content Services with permission from Health Daily Digest....